Other emerging SFK inhibitors with high specificity against HCK include A-419259 [118], which blocks proliferation and induces apoptosis in CML cell lines, as well as RK-20449 [142], which promotes tumor regression in a mouse xenograft model. This evidence concerns the gene HCK and chronic myelogenous leukemia, BCR-ABL1 positive.